Status:
UNKNOWN
Personalized Precision Diagnosis and Treatment of Pancreatic Cancer
Lead Sponsor:
Changhai Hospital
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
Pancreatic cancer (PC) is the 4th common cancer in the world and occupied the second place for digestive tumors, of which the incidence has also increased sharply in China. It harbors a particularly p...
Detailed Description
Tumor cells are released from the primary tumor and/or metastatic sites into blood. Circulating tumor cells (CTC), as a part of liquid biopsy, is acted as a new method to diagnose cancer. Many studies...
Eligibility Criteria
Inclusion
- Undergoing radical resection of pancreatic cancer;
- No serious underlying disease;
- No preoperative chemotherapy;
- The diagnosis of pancreatic cancer;
- No significant heart, lung or renal function;
- No HIV or syphilis infection;
- All patients should sign the informed consent.
Exclusion
- Preoperative general condition was poor, and it was estimated that the operation and postoperative chemotherapy and targeted therapy could not be tolerated;
- Patients with unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, cardiac infarction in the past 6 months, and prolonged QT interval (\>450ms).
- Patients with other malignancies in the last 5 years.
- Patients are not subject to follow-up or other clinical trials.
Key Trial Info
Start Date :
November 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04373928
Start Date
November 10 2017
End Date
December 31 2024
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital
Shanghai, China, 200433